Big Pharma Giants Continue to Outpace Expectations After Hiking Prices

New first quarter earnings reports released this week from Big Pharma giants Merck, Novartis and Pfizer demonstrate yet again that price hikes continue to support cushy profits for brand name drug companies. All three pharmaceutical manufacturers beat Wall Street expectations for the first quarter of 2020.

Merck reported sky-high sales this week, beating Wall Street expectations.

Novartis also kept the good times rolling by growing sales this quarter.

Pfizer also reported strong earnings.

And while price-gouging American patients is keeping profits high for Pfizer, the introduction of a generic version to the company’s block buster pain medication Lyrica demonstrates how increased competition in the marketplace is working elsewhere to lower prices.

Sales of Lyrica dipped 37 percent this quarter after the drug began facing generic competition last year — providing patients with more affordable alternatives.

The strong earnings reports come as all three companies have continued to hike prices on their prescription drugs.




See how other brand name drug makers Sanofi, Eli Lilly, Roche and Johnson & Johnson beat Wall Street expectations after hiking prices on American patients HERE, HERE, HERE and HERE.

Stay tuned this week as we continue to monitor Q1 earnings announcements from brand name drug companies.


Sign-up for updates

  • This field is for validation purposes and should be left unchanged.